Nusayba Bagegni, MD

Medical Oncologist

Nusayba Bagegni

Appointment Options

Whether you’re seeking a new patient appointment or exploring treatment options and looking for a second opinion, our Siteman care coordinators are ready to assist you.

My Locations

Gary C. Werths Building at Siteman Cancer Center

Gary C. Werths Building at Siteman Cancer Center

On WashU Medicine Campus
4500 Forest Park Avenue, Saint Louis, MO 63108
Siteman Cancer Center at Barnes-Jewish West County Hospital

Siteman Cancer Center at Barnes-Jewish West County Hospital

Medical Office Building 2, 10 Barnes West Drive, Creve Coeur, MO 63141

Expertise & Training

Clinical Expertise

  • Breast Cancer

Primary Academic Title

Associate Professor of Medicine, Division of Medical Oncology, WashU Medicine

Board Certification

  • 2013: American Board of Internal Medicine
  • 2018: American Board of Internal Medicine, Medical Oncology
  • 2018: American Board of Internal Medicine, Hematology

Training

  • 2010 - 2013: Resident, Internal Medicine, WashU Medicine, St. Louis, MO
  • 2015 - 2016: Fellow, Hematology/Oncology, WashU Medicine, St. Louis, MO
  • 2016 - 2018: Co-Chief Fellow, Hematology/Oncology, WashU Medicine, St. Louis, MO

Education

  • 2010: MD, University of Iowa, Iowa City, IA

Research & Selected Publications

Research Interest

Breast cancer clinical trials, developmental therapeutics, HER2 positive breast cancer, metastatic breast cancer

Research Publications

HER2-Low and HER2-Ultralow Metastatic Breast Cancer and Trastuzumab Deruxtecan: Common Clinical Questions and Answers
Authors:

Bagegni NA, Giridhar KV, Stewart D

Journal & Year:

Cancers (Basel) | 2025

Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer
Authors:

Ademuyiwa FO, Ma CX, Weilbaecher K, one or more additional authors omitted Bagegni N, one or more additional authors omitted Davis A

Journal & Year:

Clin Cancer Res | 2025

Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
Authors:

Hensing WL, Gerratana L, Clifton K, one or more additional authors omitted Bagegni NA, one or more additional authors omitted Davis AA

Journal & Year:

Clin Cancer Res | 2023